Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies

Watari, Kei; Konnai, Satoru; Okagawa, Tomohiro; Maekawa, Naoya; Sajiki, Yamato; Kato, Yukinari; Suzuki, Yasuhiko; Murata, Shiro; Ohashi, Kazuhiko

Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies

Watari, Kei; Konnai, Satoru; Okagawa, Tomohiro et al.

Journal of veterinary medical science, 2021, 84(1), 6-15

Permalink : https://hdl.handle.net/2115/84735

このアイテムのアクセス数:591件（2026-02-16 11:39 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1292/jvms.21-0552			2

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/84735
タイトル	Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies
著者	Watari, Kei ; Konnai, Satoru ; Okagawa, Tomohiro ; Maekawa, Naoya ; Sajiki, Yamato ; Kato, Yukinari ; Suzuki, Yasuhiko ; Murata, Shiro ; Ohashi, Kazuhiko
著者名 Watari, Kei
e-Rad_Researcher 40396304 著者名 Konnai, Satoru
e-Rad_Researcher 80829036 著者名 Okagawa, Tomohiro
e-Rad_Researcher 70829035 著者名 Maekawa, Naoya
著者名 Sajiki, Yamato
著者名 Kato, Yukinari
e-Rad_Researcher 90206540 著者名 Suzuki, Yasuhiko
e-Rad_Researcher 10579163 著者名 Murata, Shiro
e-Rad_Researcher 90250498 著者名 Ohashi, Kazuhiko
言語	英語
キーワード	cattle
	chimeric antibody
	cytotoxicT lymphocyte antigen 4
	interleukin-2
	programmed death-ligand 1
発行日	2021-11-18
出版者	公益社団法人日本獣医学会 (The Japanese Society of Veterinary Science)
収録物名	Journal of veterinary medical science
巻(号)	84(1)
ページ	6-15
抄録	Our previous studies demonstrate the therapeutic efficacy against bovine diseases of an anti-bovine programmed death-ligand 1 (PD-L1) chimeric antibody. In humans, PD-1 and PD-L1 antibodies are more effective when combined with an antibody targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and these combination therapies are therefore clinically used. Here we generated an anti-bovine CTLA-4 chimeric antibody (chAb) to enhance the therapeutic efficacy of the PD-L1 antibody. We further analyzed the effects of dual blockade of CTLA-4 and PD-1 pathways on T-cell responses. The established anti-bovine CTLA-4 chAb showed comparable blocking activity on the binding of bovine CTLA-4 to CD80 and CD86 as the anti-bovine CTLA-4 mouse monoclonal antibody. Anti-bovine CTLA-4 chAb also significantly increased IL-2 production from bovine peripheral blood mononuclear cells (PBMCs). Further, the combination of anti-CTLA-4 chAb with anti-PD-L1 chAb significantly upregulated IL-2 production by PBMCs. These results suggest that the combination of antibodies have higher potential to enhance immune responses against pathogens compared with single administration.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	0916-7250
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1292/jvms.21-0552